Abstract Vincristine-adriamycin-dexamethasone (VAD) regimen with intermittent high-dose
dexamethasone (HD) has been used as primary chemotherapy for multiple myeloma (MM) …

Methods All MM patients who received BsAb therapy on a range of clinical trials between 1st
January 2018 and 30th May 2022 at Peter MacCallum Cancer Centre were included in this …

Objectives We aimed to study whether ciprofloxacin prophylaxis reduces infectious
complications in patients undergoing autologous haematopoietic cell transplantation …

Background: Lenalidomide is an immune modulator, approved for use since 2005 for the
treatment of multiple myeloma (MM) patients. Its use is associated with an increased risk of …

Objective To explore the clinical features of infection in multiple myeloma (MM) undergoing
autologous hematopoietic stem cell transplantation (ASCT). Methods Thirty-seven patients …

A phase II multicenter trial was conducted to analyze the efficacy and safety of a bortezomib-
containing regimen for induction prior to autologous stem cell transplantation (ASCT) in …

Infectious complications are an important risk factor for early mortality in patients with
multiple myeloma. However, data about the impact and severity of infections in these …

Increased susceptibility to bacterial infections is a common manifestation of multiple
myeloma (MM), arising mainly from a defect in humoral immunity and is associated with …

METHODS We conducted a retrospective cohort from a tertiary referral center in Mexico City.
We included patients diagnosed with MM according to the International Myeloma Working …

Abstract Introduction: Multiple Myeloma (MM) remains incurable despite the advances made
with the drugs such as proteasome inhibitors, immunomodulatory agents, antibodies, and …